“2012 finished up on the choppy side, with slowing 2-yr comps and a ’13 outlook muddied by Super Supplements integration expenses, near-term headwinds from the new DC, and delayed new store openings. The set-up was tough to begin with, as VSI shares had soared +10.2% YTD vs. +4.3% for the S&P, helped by a solid GNC print. Unfortunately, as we saw recently with WFM, high-growth, high-multiple stocks have little margin for error. Bottomline: 2013 will be a year of investment, which should position VSI well for share gains, comps, leverage and stronger EPS growth in ’14 and beyond. But, at 22x our FY13E EPS, the shares look fairly valued given near-term uncertainty. Hold.,” the firm’s analyst commented.
Shares of Vitamin Shoppe traded down 0.74% during mid-day trading on Wednesday, hitting $52.16. Vitamin Shoppe has a 52 week low of $41.62 and a 52 week high of $65.93. The stock’s 50-day moving average is currently $60.19. The company has a market cap of $1.574 billion and a P/E ratio of 26.01.
Several other analysts have also recently commented on the stock. Analysts at Robert W. Baird cut their price target on shares of Vitamin Shoppe from $70.00 to $65.00 in a research note to investors on Wednesday. They now have an outperform rating on the stock. Separately, analysts at Wedbush reiterated a neutral rating on shares of Vitamin Shoppe in a research note to investors on Tuesday. Finally, analysts at Wedbush cut their price target on shares of Vitamin Shoppe to $54.00 in a research note to investors on Tuesday.
Six analysts have rated the stock with a buy rating, one has assigned an overweight rating, and eight have given a hold rating to the company’s stock. The company presently has a consensus rating of overweight and a consensus target price of $62.91.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.